WASHINGTON — Both MicroShunt implantations and trabeculectomies in patients with glaucoma on maximum tolerated medical therapy resulted in reductions in IOP and supplemental glaucoma medications 1 year postoperatively, according to a speaker here.
“If you look at the MicroShunt group specifically, 53.9% of the patients experienced a 20% or greater decrease in the mean diurnal IOP from baseline,” Doug Baker, MD, said at the American Glaucoma Society annual meeting.
Baker presented the 1-year results of a planned 2-year, randomized, single-masked multicenter study. In total, 395
Uncategorized